Business Wire

NY-METLIFE

15.10.2020 11:02:06 CEST | Business Wire | Press release

Share
MetLife Announces Senior Leadership Changes

MetLife, Inc. (NYSE: MET) today announced a number of changes to its senior leadership team. All changes are effective on January 1, 2021, unless otherwise noted.

Executive Vice President and President of the Latin America region Oscar Schmidt will retire after a distinguished 26-year career with the company. He will step away from his executive position on December 31, 2020, and will stay on through the end of March 2021 to assist with the leadership transition.

“Over the past two and a half decades, Oscar has helped us grow and develop our Latin America business, building a well-diversified portfolio of businesses across the region,” said MetLife President and CEO Michel Khalaf. “Under his strong leadership, we have grown to become the largest life insurer in Latin America – a distinction achieved organically and through a number of acquisitions.”

Succeeding Schmidt as Regional President, Latin America, will be Eric Clurfain , Executive Vice President and Chairman, President and CEO of MetLife Japan K.K., subject to the necessary approvals. He will report to Khalaf.

“With more than two decades of insurance experience, Eric has a proven track record of building high-performing teams and businesses and a deep commitment to our associates and customers,” Khalaf said. “Over the past two years, his intense focus on business execution and customer centricity has driven culture change in Japan and delivered strong results in support of our Next Horizon strategy. Under his leadership, I am confident LatAm will continue to be a growth engine for MetLife.”

Clurfain’s career path has spanned numerous geographies and strategic leadership responsibilities. Prior to his current role, Clurfain was Regional Head for EMEA with oversight over the region’s 25 markets. Previously, he was Regional Head for Central and Eastern Europe after serving as General Manager of MetLife in Turkey. Earlier in his career with AIG/Alico, Clurfain lived and worked in Latin America.

Succeeding Clurfain as Executive Vice President and Chairman, President and CEO of MetLife Japan K.K. will be Dirk Ostijn , Head of EMEA, subject to the necessary approvals. Ostijn will report to Executive Vice President Kishore Ponnavolu , Regional President, Asia.

“Dirk has successfully led our EMEA region through a challenging operating environment,” Khalaf said. “Under his leadership, the EMEA team built strong momentum with a robust pipeline of new business opportunities, a relentless focus on efficiency, and a diversified model spanning more than 25 markets. I know his exemplary leadership, deep insurance expertise, and passion for the customer will be welcomed and appreciated by our team in Japan.”

With more than 30 years of experience, Ostijn’s career encompasses all aspects of the life insurance industry, including product, finance, operations, customer service and technology. He also spent more than a decade managing insurance brokerage operations, served as a General Manager in Belgium and held regional roles such as chief financial officer and head of strategic initiatives.

Succeeding Ostijn as Head of EMEA will be Nuria Garcia , Senior Vice President and Deputy Head of EMEA. She will report to Khalaf.

“Nuria has a strong focus on business development and partnerships as well as a passion for the customer,” Khalaf said. “She is a highly effective leader who can connect internal and external stakeholders to collaborate across business, function and market. Her leadership played an integral role in the region’s continued strong performance, and I have every confidence that she will continue to build on this track record going forward.”

Garcia has more than 20 years of experience in EMEA spanning distribution, marketing, operations and finance, both with MetLife and GE.

“Taken together, these moves demonstrate not only our commitment to talent development and succession planning, but our deep bench of leaders who are ready to step up immediately and deliver value to our customers and shareholders,” Khalaf said.

About MetLife

MetLife, Inc. (NYSE: MET), through its subsidiaries and affiliates ("MetLife"), is one of the world's leading financial services companies, providing insurance, annuities, employee benefits and asset management to help its individual and institutional customers navigate their changing world. Founded in 1868, MetLife has operations in more than 40 markets globally and holds leading positions in the United States, Japan, Latin America, Asia, Europe and the Middle East. For more information, visit www.metlife.com .

Forward-Looking Statements

The forward-looking statements in this disclosure, using words such as “will,” are based on assumptions and expectations that involve risks and uncertainties, including the “Risk Factors” MetLife, Inc. describes in its U.S. Securities and Exchange Commission filings. MetLife’s future results could differ, and it has no obligation to correct or update any of these statements.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Klarna Agrees to $1.7 Billion Transaction Supporting up to $40B+ of Lending1.4.2026 13:19:00 CEST | Press release

Klarna, the global digital bank and flexible payments provider, has entered into a new capital efficiency transaction in the form of a Significant Risk Transfer (SRT), covering $1.7 billion-worth of Euro denominated loans and freeing up capital to support continued growth. Klarna has entered into a three-year agreement with a consortium led by Värde Partners. This is Klarna's sixth SRT transaction and improves how effectively Klarna deploys its capital on a global basis. "Our banking license is one of our biggest competitive advantages," said Niclas Neglén, Klarna's Chief Financial Officer. "This is our largest and most efficient SRT transaction to date. These transactions allow us to maximize every unit of capital to support our continued momentum." The transaction follows Klarna’s recently announced $2 billion facility supporting $17B of US Financing expansion. About Klarna Klarna is a global digital bank and flexible payments provider. With over 118 million global active Klarna user

Americhem Launches nDryve™: PFAS-Free In-Melt Technology Platform for Functional Fibers1.4.2026 13:00:00 CEST | Press release

Americhem, Inc., a global polymer solutions provider, today announced the launch of nDryve™, a PFAS-free, in-melt surface-modifying technology platform designed to deliver durable multi-fluid repellency against alcohol and other low-surface-energy fluids in fiber systems. As global regulations accelerate the phase-out of per- and polyfluoroalkyl substances (PFAS), manufacturers are under increasing pressure to maintain barrier performance without fluorinated chemistries. nDryve™ was developed to address this shift, offering a PFAS-free, in-melt alternative to conventional surface applied treatments. Engineered for Performance Without PFAS Often referred to as “forever chemicals,” PFAS have come under heightened regulatory scrutiny due to their persistence and potential environmental and health impacts. nDryve™ integrates directly into the polymer during melt processing, embedding surface-modifying functionality within the fiber matrix rather than relying on removable finishes. By engin

Biocytogen and Sihuan Pharmaceutical Announce Strategic Partnership in Weight Loss and Beyond1.4.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced a strategic partnership with Sihuan Pharmaceutical Holdings Group Ltd. (Sihuan Pharmaceutical; HKEX: 00460). Under the agreement, both parties will combine Biocytogen’s leading fully human antibody discovery platform with Sihuan Pharmaceutical’s extensive capabilities in drug development, manufacturing, and commercialization. The collaboration will focus on advancing innovative therapies across multiple disease areas, including weight loss, leveraging complementary strengths to drive synergies and establish a long-term strategic partnership. Sihuan Pharmaceutical highly values the strength of Biocytogen’s technology platforms. In this collaboration, Biocytogen will leverage its integrated platforms, including proprietary target-humanized mouse models and

Huawei, LG Electronics and Nokia Named as Founder Licensors of New Sisvel POS Pool1.4.2026 12:17:00 CEST | Press release

Three world-class innovators are the founder licensors of the new Point of Sale (POS) patent pool, covering 2G to 5G technology, which Sisvel has launched today. Huawei, LG Electronics and Nokia have made their standard essential patents (SEPs) reading on cellularly connected POS devices available through the programme, so simplifying access to the increasingly ubiquitous technology. Early participation incentives for licensors to join the pool are available until mid-May. Other cellular patent owners not currently in discussions with Sisvel are encouraged to get in touch. Ranging from handheld card machines to tablet-based registers, POS devices have transformed customer payment processing. Increasingly, they also offer enhanced capabilities such as inventory management, real-time tracking, advanced analytics and automatic re-ordering. Standardised cellular technology is the critical feature that enables POS terminals to function wherever customers are located. The Sisvel POS programm

Mosaic Therapeutics appoints Dr Vince O'Neill, MD, as Head of R&D1.4.2026 11:11:00 CEST | Press release

- Medical oncologist and accomplished clinical leader brings deep development and industry experience to Mosaic’s Executive Leadership team - Vince will lead research and development for Mosaic’s drug combination programs, including the build-out of the Company’s early pipeline Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company developing next-generation, Synergistic Precision combination therapies, today announced the appointment of Dr Vince O’Neill as Head of Research and Development (R&D) to support its next phase of growth. “We are delighted to welcome Vince to the Mosaic leadership team at this pivotal stage of the company’s evolution,”said Thomas Fuchs, CEO, Mosaic Therapeutics.“His deep expertise in targeted oncology drug development and diagnostics will be instrumental as we advance our pipeline to bring transformative therapies to patients in need.” Vince is a board-certified medical oncologist and highly experienced biotechno

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye